Non-small Cell Lung Cancer Stage III

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

HEARTS Trial for Thoracic Cancers

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC